Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 17.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 974,173 shares of the company's stock after purchasing an additional 141,582 shares during the quarter. Bank of America Corp DE owned about 1.86% of 4D Molecular Therapeutics worth $9,070,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC increased its position in 4D Molecular Therapeutics by 164.4% in the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company's stock worth $34,726,000 after buying an additional 2,882,508 shares during the period. State Street Corp boosted its holdings in shares of 4D Molecular Therapeutics by 197.5% during the fourth quarter. State Street Corp now owns 2,688,880 shares of the company's stock valued at $20,167,000 after acquiring an additional 1,785,106 shares during the period. RA Capital Management L.P. grew its position in shares of 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company's stock worth $42,399,000 after acquiring an additional 1,090,000 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company's stock worth $9,264,000 after acquiring an additional 1,060,156 shares during the last quarter. Finally, Evergreen Quality Fund GP Ltd. acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth about $7,136,000. Institutional investors and hedge funds own 99.27% of the company's stock.
Insider Activity at 4D Molecular Therapeutics
In related news, insider Scott Bizily sold 9,810 shares of the firm's stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider owned 8,617 shares in the company, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Kirn sold 114,746 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the sale, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 200,496 shares of company stock valued at $2,240,244 over the last quarter. Insiders own 7.90% of the company's stock.
4D Molecular Therapeutics Stock Performance
Shares of FDMT opened at $15.39 on Tuesday. The firm has a 50-day moving average price of $11.74 and a 200 day moving average price of $10.17. The firm has a market capitalization of $850.14 million, a PE ratio of -5.85 and a beta of 2.73. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 52-week low of $5.97 and a 52-week high of $16.93.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts recently weighed in on FDMT shares. HC Wainwright reissued a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. The Goldman Sachs Group restated a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Wall Street Zen downgraded 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Finally, Chardan Capital raised 4D Molecular Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.62.
Check Out Our Latest Report on 4D Molecular Therapeutics
4D Molecular Therapeutics Profile
(
Free Report)
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Featured Stories
Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
